Alizyme

What Alizyme does

Alizyme is a privately held drug development company founded in 1997 and headquartered in Cambridge, United Kingdom. Per its stated corporate identity, the company develops new pharmaceutical products targeting diseases with high unmet medical need and substantial market opportunity, with historical focus areas including obesity and related metabolic conditions such as diabetes, gastrointestinal disorders (irritable bowel syndrome and inflammatory bowel disease), and mucositis arising as a side effect of cancer therapy. Its technical base consists of four clinical-stage drug product candidates for which Alizyme owns full intellectual property rights, complemented by an exclusive worldwide licence to the COLAL drug delivery system for targeted gastrointestinal drug delivery. The company takes candidates from early stage into clinical development and aims to license products to pharmaceutical partners for late-stage development, regulatory approval, and commercialisation.

Alizyme operates an asset-light model, outsourcing laboratory and development work to contract research organisations and specialist advisors under the control of a small core management team. This structure is intended to concentrate capital on development programmes rather than fixed infrastructure. No pricing, revenue, headcount, partner, or funding data is disclosed in the source material, and there are no named licensees or collaborations, which limits visibility into commercial traction.

A material discrepancy exists in the input data: while firmographic and legal records describe a UK-based pharmaceutical R&D company, the live alizyme.com website at the time of capture simultaneously displays the drug-development corporate narrative and a stream of consumer-facing editorial reviews of third-party dietary supplements (e.g., testosterone boosters, fat burners, nootropics, joint-health, and gut-health products). This dual presence is not reconciled in the source and is noted here as a data-integrity flag rather than asserted as a confirmed pivot.

Name

Alizyme

Legal name

Alizyme

Website

https://alizyme.com

Company type

Private

Founded year

1997

Operating status

Operating

Short description

Alizyme is a privately held Cambridge, UK-based drug development company that takes gastrointestinal and metabolic disease candidates (obesity, diabetes, IBS, IBD, mucositis) into clinical trials and licenses them to pharmaceutical partners for late-stage development and commercialisation.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Drug development
• Clinical stage pharmaceuticals
• Gastrointestinal therapeutics
• Metabolic disease drugs
• Pharmaceutical licensing

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Distribution channels1 record

Core offering

Alizyme is a drug development company that takes drug product candidates from an early stage into clinical development, with the objective of demonstrating efficacy in patients and providing a comprehensive data package to support further development and commercialisation. The company focuses on gastrointestinal disorders (IBS, IBD), metabolic diseases (obesity, diabetes) and mucositis. Alizyme owns the IP rights to all four clinical-stage drug products and holds an exclusive worldwide licence to the COLAL drug delivery system, aiming to license its products to pharmaceutical companies at a suitable stage.

Product overview

Alizyme is a health and wellness review platform (not a product manufacturer) that publishes comprehensive reviews and comparisons of third-party dietary supplements. The site's offerings consist of editorial product reviews across categories including testosterone boosters (Testogen, TestoPrime), fat burners (PhenQ, PhenGold, Phen375, Zotrim, Trimtone, Primeshred), nootropics (NooCube, Alpha Brain, Prevagen), joint health supplements (Icelandic Red Algae Calcium, Performance Lab Flex), gut health products (Biotics 8), and male enhancement supplements (Performer 8, VigRX Plus). The company itself was historically a drug development company focused on obesity, diabetes, and gastrointestinal disorders, but the current website functions as an affiliate review content platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical-stage drug candidates for gastrointestinal disorders (IBS and IBD) Drug product candidates taken from early stage into clinical development to treat irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Offered for out-licensing to pharmaceutical companies capable of completing clinical development, securing regulatory approval and marketing the products.
• Clinical-stage drug candidates for obesity and related metabolic diseases (including diabetes) Drug product candidates in clinical development for obesity and related metabolic diseases such as diabetes, focused on indications with high unmet medical need and substantial market opportunity. Offered for out-licensing to pharmaceutical partners for late-stage development and commercialisation.
• Clinical-stage drug candidates for mucositis (cancer therapy side effect) Drug product candidates for treatment of mucositis, a serious side effect of cancer therapy. Developed through clinical-stage programmes and offered for out-licensing to pharmaceutical companies for further development, regulatory approval and commercialisation.
• COLAL drug delivery system (out-licensed via drug products) Exclusive worldwide licensed drug delivery system for targeted gastrointestinal drug delivery, used to formulate Alizyme's clinical-stage candidates and offered to pharmaceutical licensees as part of the licensed product package.

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Orexigen Therapeutics: Historically a clinical-stage obesity drug developer that pursued a licensing deal with a major pharma for commercialization. Comparable given its obesity focus, asset-light development model, and licensing-out pathway.
• Norgine: European specialty pharma with a focused GI portfolio and a licensing/out-licensing model. Comparable to Alizyme given its GI therapeutic focus, European base, and B2B pharma partnership orientation.
• Zealand Pharma: Clinical-stage metabolic disease company developing peptide therapeutics for obesity and diabetes. Comparable given its metabolic disease focus, clinical-stage profile, and reliance on pharma partners for commercialization.
• Ironwood Pharmaceuticals: US-based clinical-stage and commercial GI specialty company developing therapies for IBS and related GI disorders. Directly comparable to Alizyme's IBS/IBD focus and clinical-stage, small-molecule gastrointestinal pipeline.
• Arena Pharmaceuticals: Clinical-stage metabolic/GI drug developer that was acquired by a major pharma for its pipeline assets. Comparable given its clinical-stage metabolic disease pipeline and its outcome of being acquired for pipeline value.
• Vivus (VIVUS Inc.): Clinical-stage obesity/metabolic disease developer that has historically pursued licensing deals for its metabolic assets. Directly comparable given its obesity therapeutic focus and reliance on partner commercialization.
• Alfasigma: European specialty pharmaceutical company with a strong gastrointestinal and metabolic disease franchise. Comparable as a privately held GI/metabolic-focused drug developer and licensor across similar indications.

Emerging players

• Albireo Pharma: Clinical-stage developer of novel bile acid and GI-targeted therapeutics. Comparable as a smaller clinical-stage company with a specialized GI mechanism of action and out-licensing orientation.
• RedHill Biopharma: Clinical-stage specialty pharma focused on gastrointestinal and infectious diseases. Comparable given its GI therapeutic focus and small-cap clinical-development profile with partner-driven commercialization.

Broad incumbents

• Salix Pharmaceuticals: Established US specialty GI pharmaceutical company with a broad marketed GI portfolio. Relevant comparable given its dominant GI focus and the same prescriber base that would adopt Alizyme's GI candidates post-licensing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alizyme